Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Trelegy Ellipta is the only triple therapy shown to reduce moderate severe exacerbations vs BUD/GLY/FOR in patients who need to step-up from dual therapy (LAMA/LABA or ICS/ LABA)3
Real-world evidence for Trelegy Ellipta (fluticasone furoate/ umeclidinium/vilanterol) in patients with COPD
Insights from 2 separate real world comparative effectiveness studies in patients with COPD stepping up from dual therapy
Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol) is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA) or a combination of a LABA and a long-acting muscarinic antagonist (LAMA).1
The real-world evidence for Trelegy Ellipta is building
Evidence that makes a difference to patients and practice
Trelegy Ellipta: A triple therapy shown to improve quality of life and patient outcomes while reducing healthcare burden3,4
In a retrospective real-world weighted cohort comparative effectiveness study (CES) of patients with COPD previously treated with dual therapy (LAMA/LABA or ICS/LABA) in the USA
RWE for Trelegy Ellipta vs Trixeo (BUD/GLY/FOR)
Results are reflective of the population studied and may not be generalisable.
Primary outcome: Annualised rate of moderate-severe COPD exacerbations between patients treated with FF/UMEC/VI and BUD/ GLY/FOR who used dual therapy as their latest treatment before stepping up. All-Cause Mortality was an exploratory endpoint. While exploratory findings may provide valuable insights, they are not typically designed to demonstrate definitive clinical efficacy.
Find out more about the product
VIDEO: Watch real world Trelegy Ellipta COPD insights (CES)
Professor Wisia Wedzicha of Imperial College London explores the real-world evidence from the Comparative Effectiveness Study.
GSK resources for COPD management
Abbreviations:
BEGF: beclometasone/glycopyrronium/formoterol; BUD/GLY/FOR: budesonide/glycopyrronium/formoterol; CES: comparative effectiveness study; CI: confidence interval; HR: hazard ratio; ICS: inhaled corticosteroid; KM: Kaplan meier; LABA: long-acting beta agonist; LAMA: long-acting muscarinic antagonist; pMDI: pressured meter dose inhaler; RCTs: randomised controlled trials; RR: risk ratio
References:
- Trelegy Ellipta Summary of Product Characteristics.
- Cherian M et al. Int J COPD 2026;21:585037.
- Wedzicha JA et al. Adv Ther 2025; 42(9):4432-4446.
- Lipson DA et al. Am J Respir Crit Care Med 2017;196(4):438-446.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com.
July 2026 | PM-GB-FVU-WCNT-260003 (V1.0)
